Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

897 questions · 966 findings · 73 reviews

No studies found 269 · 27.8%GRADE not reported 101 · 10.5%Very low 284 · 29.4%Low 180 · 18.6%Moderate 107 · 11.1%High 25 · 2.6%

Medical or surgical intervention, or both, for gastro‐oesophageal reflux disease vs nil intervention, delayed intervention control, or placebo

Healthcare utilisation ‐ not measured · treatment for asthma in adults and children with asthma and GORD

The review found no eligible studies for this question.

1 finding from 1 review

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Depressive symptoms · treatment‐resistant depression in adults

Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Remission · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with busiprone (20… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI) with placebo (low certainty).

1 finding from 1 review

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Leaving the study early · treatment‐resistant depression in adults

Switching to mianserin (60 mg/d) showed no clear difference in dropouts compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

1 finding from 1 review